Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission

Inclusion Criteria: * Patients with non-metastatic, node positive, HER2 negative breast cancer, confirmed by pathology report, who are in remission and defined as having no evidence of disease (NED); HER2 negative is defined as * 0-1+ HER2 expression by immunohistochemistry (IHC) OR * Fluorescence in situ hybridization (FISH) negative OR * HER2 2+ and FISH negative * Patients must be at least 28 days post cytotoxic chemotherapy, radiotherapy, monoclonal antibody and/or other biologic therapy, prior to enrollment; patients on bisphosphonates, denosumab, and/or endocrine therapy administered during the study are eligible and may continue throughout duration of study * Patients must be at least 28 days post systemic steroids prior to enrollment * Patients must have Eastern Cooperative Oncology Group (ECOG) performance status score of =\< 2 * White blood cell (WBC) \>= 3000/mm\^3 * Hemoglobin (Hgb) \>= 10 g/dl * Lymphocyte count \>= 800/mm\^3 * Platelet count \>= 75,000/mm\^3 * Serum creatinine =\< 2.0 mg/dl or creatinine clearance \> 60 ml/min * Total bilirubin =\< 1.5 mg/dl * Aspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT) =\< 2 times upper limit of normal (ULN) * Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment * The effects of WOKVAC on the developing human fetus are unknown. Fo…